Guidelines

The Joint Task Force on Practice Parameters GRADE guidelines support clinicians and patients in the medical management of CRSwNP.¹ The most recent complete guidelines were published in 2014.¹ Updated guidelines published in 2022 consider current evidence for the use of intranasal corticosteroids (INCS) and biologics but not surgery or other alternative management options.¹

Additional sources of guidance for CRSwNP management include:

American Academy of Otolaryngology—Head and Neck Surgery Foundation (AAO-HNS) last updated in 2015²
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis last updated in 2021 (ICAR-RS-2021)³
European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) released in 2020⁴
European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) released updated EPOS/EUFOREA guidelines for the use of biologics for CRSwNP in 2023⁵
Criteria for the indication of treatment with biologics for CRSwNP according to the updated EPOS/EUFOREA guidelines (2023)⁵

References

Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023;151(2):386-398.
Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-S39.
Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023;61(3):194-202.